The ECHELON-2 trial was a multinational double-blind randomized trail randomizing patients with ALCL and other CD30-positive PTCLs to receive either CHP (cyclophosphamide, doxorubicin, prednisone) and BV, or standard CHOP (cyclophosphamide, doxorubicin, Oncovin, prednisone). This evidence concerns the gene TNFRSF8 and anaplastic large cell lymphoma.